In this company update, CEO, Matthew Mills informs the shareholders on the new relationship with Investor Relations Firm MZ North America. Matthew informs the shareholders on the company's continued focus to gain access to the $100 Million in capital from GEM. Matthew also discusses changes to the Board of Directors as well as an update on international sales and marketing opportunities.
In order for the company to gain access to the $100 Million commitment from GEM it must list on a public exchange. As preparations continue to move forward the management team has engaged with the reputable Investor Relations group, MZ North America. MZ has a proven track record of successfully supporting private and publicly traded companies. With their experience with servicing publicly traded companies like, Fed-Ex, Cisco, D-Link and many others, we feel confident that they will provide the same level of support and communication the company’s shareholders currently have. This is the next step in the company’s long term plans.
Changes have also been made at the management level with Dr. Toomey moved from the CEO to Chief Science Officer, Matthew Mills taking over the role of Chief Executive Officer and Jennifer Mills also being promoted to President. Two new board positions were also announced. The details of these changes can be found on the file from SEC Form 1-U medx_1u.htm (sec.gov).
Marketing commitments for 2022 are now in place and because of all the support from our shareholders we are confident that it will be a fruitful investment for 2022 and beyond. We have committed to robust marketing plans with all of our major distributors. These early commitments put the Nature-Cide and Thermal-Aid brands in a position they have never been before. The focus to grow these divisions in the retail space is very exciting. Ecommerce also continues to grow as we enter into the busiest time of year with lots of resources being pushed to finish Q4 strong.
The expansion of the Nature-Cide brands into several international markets continues its long arduous journey through getting approval and registration in each country. As Matthew described, we are nearing the end of the process for Mexico and Australia while Canada and the UK are just in the beginning stages.
Thus far 2021 has been a fantastic year full of many important achievements. The focus of this year was to position the company in a way that the management team felt comfortable to start planning to take it to a national exchange. With the commitment from GEM for the $100 Million once the company is listed, the company’s management team feels really good about moving into 2022 with a solid plan to continue to grow the company and continue to offer its shareholders more value.
Without your support over the years we would not be in this position. It has taken all of us, each shareholder and team member, to make this happen. We look forward to finishing the year strong and entering 2022 with great momentum.
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.